Tag: xbiotech

December 31, 2019

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson's Janssen Biotech.
November 12, 2019

XBiotech Doses First Patient in Clinical Study of Bermekimab

The company is evaluating its IL-1a blocking antibody therapy in patients with moderate-to-severe Atopic Dermatitis (AD).
October 2, 2019

XBiotech Doses First Patient in Clinical Study

The company announced the first patient was enrolled in a clinical study in adults with systemic sclerosis.
January 23, 2019

Bermekimab Successfully Treats Hidradenitis Suppurativa, Including Significant Reduction in Pain

XBiotech (NASDAQ: XBIT) announced the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with...
December 30, 2018

5 Top Weekly NASDAQ Biotech Stocks: Dova Up 41 Percent

Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
December 12, 2018

XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease

XBiotech (NASDAQ:XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate...
November 4, 2018

5 Top Weekly NASDAQ Biotech Stocks: Aptose Leads this Week

Aptose Biosciences, Trevena, Curis, Geron and Aveo Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.